Jeremy P Feldman MD

Critical Care Medicine, Interstitial Lung Diseases, Interventional Pulmonology, Pleural Disease

Founder JPF Advisors Co-Founder Inspire Pulmonary Media

1501 NE Medical Center DrBend, OR 97701
Phone+1 541-382-4900
Fax+1 541-706-5273

Dr. Feldman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feldman's full profile Already have an account?

Summary

I have dedicated the past 20 years to pulmonary vascular disease and advanced lung disease.

I have created educational websites for pulmonary hypertension (pulmonaryhypertensionRN.com) and pulmonary fibrosis (pulmonaryfibrosisMD.com)

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2004
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
University of California San Diego School of MedicineClass of 1998

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2001 - 2028
AZ State Medical License 2004 - 2027
AZ State Medical License 2004 - 2027
OR State Medical License 2021 - 2027
WA State Medical License 2025 - 2026
MA State Medical License 2000 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Greenway Intergy Meaningful Use Edition, Greenway Health, LLC, 2012-2017
CMS Meaningful Use Stage 1 Certification Sage Intergy Meaningful Use Edition, Sage, 2012-2017
CMS Meaningful Use Stage 2 Certification Vitera Intergy Meaningful Use Edition, Vitera Healthcare Solutions, LLC, 2012-2017

Clinical Trials

Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
COMPLETED
PHASE2
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
COMPLETED
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
COMPLETED
PHASE3

Publications & Presentations

PubMed

9 citations
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension inMutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, ...
David Montani, Vallerie V McLaughlin, J Simon R Gibbs, Mardi Gomberg-Maitland, Marius M Hoeper
American Journal of Respiratory and Critical Care Medicine. 2025-06-01
15 citations
IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.
Hunter Gillies, Murali M Chakinala, Benjamin T Dake, Jeremy P Feldman, Marius M Hoeper
Pulmonary Circulation. 2024-01-01
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypert...
Hilary M DuBrock, Charles D Burger, Sonja D Bartolome, Jeremy P Feldman, David D Ivy
Pulmonary Circulation. 2022-10-01

Press Mentions

Phase 3 INOpulse Trial Enrolls First Patient at Risk of PF-Associated PHDecember 4th, 2020
First Patient Enrolled in Phase 3 REBUILD Trial of INOpulseDecember 4th, 2020
New Pulmonary Hypertension Association Accreditation Program and Registry Giving New Understanding to Specialists Caring for People Living with Pulmonary HypertensionFebruary 3rd, 2017